RECOURSE: What the Colorectal Cancer Trial Found

What a last-line drug is asked to do

There is a point in advanced colorectal cancer where the standard treatments have all been tried and none of them are working. RECOURSE tested a drug for exactly that point.

The expectations at that stage are different. Nobody is looking for a cure. The questions are whether a drug adds time, whether it adds good time, and whether the side effects are worth it.

Who was in the trial

800 people with metastatic colorectal cancer took part. All had disease that had stopped responding to standard treatments. They were assigned 2 to 1 to receive TAS-102, now known as trifluridine/tipiracil, or a placebo. Neither the patients nor their doctors knew which.

Comparing against a placebo is uncomfortable to read about. In a setting where no active treatment is left, it is also the only way to know whether a new drug does anything at all.

Under two extra months

Median overall survival was 7.1 months with TAS-102 and 5.3 months with placebo. The hazard ratio for death was 0.68 (95% CI 0.58 to 0.81; p<0.001), or about a 32% lower risk of dying at any moment.

On the median, that is roughly 1.8 extra months. It is a real result and a small one, and both of those things should be said plainly.

Time spent functioning, not just time alive

The measure that arguably matters more here is how long people stayed able to manage their own day.

Doctors track this with a performance status score. The trial measured how long it took to slip from being fully or mostly active to needing significant help. That took a median of 5.7 months with TAS-102 against 4.0 months with placebo (hazard ratio 0.66; 95% CI 0.56 to 0.78; p<0.001).

So the extra time was not simply added at the end in poor condition. Decline started later.

The blood-count cost

The main problem was low blood counts. Neutropenia affected 38% of people on the drug and leukopenia 21%. 4% developed a fever alongside low neutrophils, which is a medical emergency. One death was attributed to the drug.

These effects mean regular blood tests, and sometimes delays or dose reductions.

What to keep in perspective

• The gain is measured in weeks, not years. Whether that is worth the clinic visits and the side effects is a personal judgement, not a medical fact.
• The comparison was against placebo. It cannot rank this drug against other late-line options such as regorafenib.
• Everyone in the trial was well enough to be offered more treatment. People who are frailer were not represented.
• Half the group did better than the median and half did worse. Neither half is predictable in advance.

Questions when the standard options run out

• What is the realistic goal of trying another drug now?
• How would we know within a few weeks whether it is helping me?
• How often would I need blood tests and clinic visits?
• What would supportive care alone look like, and can I have both?

Sources

This article was written from the sources below, which were checked on the source-check date shown above.

• NEJM: Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer (RECOURSE) (primary)

How this article was prepared

Prepared by Cancer Explained's AI-assisted editorial system and checked against the sources listed below. This article has not been reviewed by a healthcare professional unless a named reviewer is specifically shown.

Cancer Explained is published by the National Cancer Information Foundation as a nonprofit-oriented public-interest education project. It is not a diagnostic service, does not recommend treatments, and is not for emergencies.

Found an error, a broken source link, outdated information, or wording that feels insensitive? Report it here — we log and act on material corrections.